miR-216a may inhibit pancreatic tumor growth by targeting JAK2.

FEBS letters (2015-07-08)
Bao-hua Hou, Zhi-xiang Jian, Peng Cui, Shao-jie Li, Rui-qing Tian, Jin-rui Ou

This study was aimed to investigate miR-216a expression in pancreatic cancer and determine its effects on proliferation. miR-216a was found downregulated in pancreatic cancer tissues as compared to benign pancreatic lesions. JAK2 was identified as a miR-216a gene target. Further, in vivo treatment of PANC-1 tumors with miR-216a reduced JAK2 protein levels in the tumor and reduced tumor volume. In conclusion, miR-216a may function as a tumor suppressor regulating pancreatic cancer cells by targeting the JAK/STAT pathway. Further studies with a larger number of patient samples are necessary to fully explore the diagnostic and therapeutic potential of miR-216a for pancreatic cancer.

Product Number
Product Description

Tris(tert-butoxy)silanol, packaged for use in deposition systems
Tris(tert-butoxy)silanol, 99.999%
Bicinchoninic acid disodium salt hydrate, ≥98% (HPLC)